W. K. Kelly

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

L. Schwartz, H. Scher, P. Marks, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.

J. Pignon, S. Michiels, C. Logothetis, 2007, The Lancet. Oncology.

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

P. Kantoff, S. Larson, H. Scher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.

M. Zelefsky, H. Scher, S. Leibel, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.

H. Scher, Z. F. Zhang, D. Nanus, 1996, Urology.

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study.

P. Kantoff, P. Scardino, J. Eastham, 2004, The Journal of urology.